CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026Business Wire · 2 days ago
CareDx Inc (CDNA) Shares Fall 4.0% -- GF Value Says Still OvervaluedGuruFocus · Oct 16, 2026
CareDx to Report Third Quarter 2026 Financial Results on October 29, 2026Business Wire · Oct 15, 2026
Critical Contrast: CollPlant Biotechnologies (NASDAQ:CLGN) & CareDx (NASDAQ:CDNA)Defense World · Oct 5, 2026
CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?Zacks Investment Research · Sep 25, 2026
Medicare Lab Fee Changes Impact BillionToOne, CareDx DifferentlyBenzinga · Sep 23, 2026CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 30, 2026 | $0.23 | $0.37 | Beat |
| Apr 28, 2026 | $0.11 | $0.34 | Beat |
| Feb 24, 2026 | $0.02 | $0.12 | Beat |
| Nov 4, 2025 | -$0.08 | $0.03 | Beat |
| Aug 6, 2025 | -$0.10 | -$0.16 | Miss |
| Apr 30, 2025 | -$0.21 | -$0.19 | Beat |